StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research note published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, Citigroup cut their price target on shares of Eiger BioPharmaceuticals from $4.00 to $3.00 and set a buy rating on the stock in […]

Leave a Reply

Your email address will not be published.

Previous post Mike Preston’s report card: Position-by-position grades for Ravens’ 34-20 win over the Bengals | COMMENTARY
Next post Contrasting Cincinnati Financial (NASDAQ:CINF) and Hippo (NYSE:HIPO)